Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy

Discovery Medicine

Volumn 15, Issue 80, 2013, Pages 51-60

  Verweij, Cornelis L ^a   Vosslamber, Saskia ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON;

BLOOD; HUMAN; METHODOLOGY; MULTIPLE SCLEROSIS; PERSONALIZED MEDICINE; REVIEW;

HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON TYPE I; INTERFERON-BETA; MULTIPLE SCLEROSIS;

MLCS; MLOWN;

EID: 84881300895     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Annibali V, Di GS, Cannoni S, Giugni E, Bomprezzi R, Mattei C, Elkahloun A,Coccia EM, Alfò M, Orzi F, Ristori G, Salvetti M. Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis. Autoimmunity 40:16-22, 2007.
2. Aung LL, Fitzgerald-Bocarsly P, Dhib-Jalbut S, Balashov K. Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta. J Neuroimmunol 226:158-164, 2010.
3. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16:406-412, 2010.
4. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and death. Cancer Res 63:6424-6431, 2003.
5. Bushnell SE, Zhao Z, Stebbins CC, Cadavid D, Buko AM, Whalley ET, Davis JA, Versage EM, Richert JR, Axtell RC, Steinman L, Medori R. Serum IL-17F does not predict poor response to IM IFN-β-1a in relapsing-remitting MS. Neurology, epub ahead of print, May 9, 2012.
6. Bustamante MF, Fissolo N, Río J, Espejo C, Costa C, Mansilla MJ, Lizasoain I, Moro MA, Carmen Edo M, Montalban X, Comabella M. Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis. Ann Neurol 70:634-645, 2011.
7. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8:237-249, 2003.
8. Coccia EM. IFN regulation and functions in myeloid dendritic cells. Cytokine Growth Factor Rev 19:21-32, 2008.
9. Comabella M, Lunemann JD, Rio J, Sanchez A, Lopez C, Julia E, Fernandez M, Nonell L, Camina-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R. A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis. Brain 132:3353-3365, 2009.
10. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol 142:2-8, 2012.
11. Compston A, Coles A. Multiple sclerosis. Lancet 359:1221-1231, 2002.
12. Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J, epub ahead of print, Jun. 19, 2012.
13. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta or gamma using microarrays. Proc Natl Acad Sci USA 95:15623-15628, 1998.
14. Dore-Duffy P, Washington R, Dragovic L. Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis. Adv Exp Med Biol 331:243-248, 1993.
15. Dupont SA, Goelz S, Goyal J, Green M. Mechanisms for regulation of cellular responsiveness to human IFN-beta1a. J Interferon Cytokine Res 22:491-501, 2002.
16. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 3:104-110, 2004.
17. Fernald GH, Knott S, Pachner A, Caillier SJ, Narayan K, Oksenberg JR, Mousavi P, Baranzini SE. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J Immunol 178:5076-5085, 2007.
18. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, González Escribano MF; Argentine and Spanish Collaborative Groups, Pons-Estel B, Petri M, Daly M, Gregersen PK, Martín J, Altshuler D, Behrens TW, Alarcón-Riquelme ME. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38:550-555, 2006.
19. Gresser I. Biologic effects of interferons. J Invest Dermatol 95:66S-71S, 1990.
20. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Förster I, Farlik M, Decker T, Du Pasquier RA, Romero P, Tschopp J. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34:213-223, 2011.
21. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL.. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357:851-862, 2007.
22. Handel AE, Jarvis L, McLaughlin R, Fries A, Ebers GC, Ramagopalan SV. Smoking and multiple sclerosis: an updated meta-analysis. PLoS One 6:e16149, 2011.
23. Hartrich L, Weinstock-Guttman B, Hall D, Badgett D, Baier M, Patrick K, Feichter J, Hong J, Ramanathan M. Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients. J Neuroimmunol 139:84-92, 2003.
24. Hilpert J, Beekman JM, Schwenke S, Kowal K, Bauer D, Lampe J, Sandbrink R, Heubach JF, Stürzebecher S, Reischl J. Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. J Neuroimmunol 199:115-125, 2008.
25. Hu G, Barnes BJ. IRF5 is a mediator of the death receptor-induced apoptotic signalling pathway. J Biol Chem 284:2767-2777, 2009.
26. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19:225-234, 2003.
27. Lehtonen A, Matikainen S, Julkunen I. Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages. J Immunol 159:794-803, 1997.
28. Luchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriquez M, Lassman H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707-717, 2000.
29. Ludigs K, Parfenov V, Du Pasquier RA, Guarda G. Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. Cell Mol Life Sci, epub ahead of print, Apr. 24, 2012.
30. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3:822-829, 2002.
31. Mirandola SR, Hallal DE, Farias AS, Oliviera EC, Branao CO, Ruocco HH, Damasceno BP, Santos LM. Interferon-β modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis. Int Immunopharmacol 9:824-830, 2009.
32. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 264:1918-1921, 1994.
33. Munafo A, Trinchard-Lugan I, Nguyen TX, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 5:187-193, 1998.
34. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832-2838, 2006.
35. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 343:938-952, 2000.
36. PaluckaAK, Blanck JP, Bennett L, PascualV, Banchereau J. Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc Natl Acad Sci U S A 102:3372-3377, 2005.
37. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 18:676-682, 2006.
38. Pedemonte E, Mancardi G, Giunti D, Corcione A, Benvenuto F, Pistoia V, Uccelli A. Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. Pharmacol Ther 111:555-566, 2006.
39. Penkowa M, Hidalgo J. Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis. J Neurosci Res 72:574-586, 2003.
40. Rani MR, Shrock J, Appachi S, Rudick RA, Williams BR, Ransohoff RM. Novel interferon-beta-induced gene expression in peripheral blood cells. J Leukoc Biol 82:1353-1360, 2007.
41. Reske D, Walser A, Haupt WF, Petereit HF. Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment. Acta Neurol Scand 109:66-70, 2004.
42. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 52:1277-1279, 1999.
43. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56:548-555, 2004.
44. Rullo OJ, Woo JM, Wu H, Hoftman AD, Maranian P, Brahn BA, McCurdy D, Cantor RM, Tsao BP. Association of IRF5 polymorphisms with activation of the interferon-α pathway. Ann Rheum Dis 69:611-617, 2010.
45. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 8:559-568, 2008.
46. Satoh J, Nanri Y, Tabunoki H, Yamamura T. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis. BMC Neurol 6:18, 2006.
47. Schoenemeyer A, Barnes BJ, Mancl ME, Latz ME, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor signalling. J Biol Chem 284:2767-2777, 2009.
48. Schwid SR, Panitch HS. Full results of the evidence of interferon dose-response-European North American comparative efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 29:2031-2048, 2007.
49. Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci 258:52-59, 2007.
50. Smolders J, Peelen E, Thewissen M, Cohen Tervaert JW, Menheere P, Hupperts R, Damoiseaux J. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 5:e15235, 2010.
51. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 23:683-747, 2005.
52. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 67:227-264, 1998.
53. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, Frank JA, Staudt L, Martin R, McFarland HF. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 126:1419-1429, 2003.
54. Sundstrom P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nyström L, Dillner J, Forsgren L. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62:2277-2282, 2004.
55. Sweeney CM, Lonergan R, Basdeo SA, Kinsella K, Dungan LS, Higgins SC, Kelly PJ, Costelloe L, Tubridy N, Mills KH, Fletcher JM. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun 25:1170-1181, 2011.
56. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623-655, 2001.
57. van Baarsen LGM, van der Pouw Kraan CTM, Kragt JL, Baggen JMC, Rustenburg F, Hooper T, Meilof JF, Fero M, Dijkstra CD, Polman CH, Verweij CL. A subtype of multiple sclerosis defined by an activated immune defence program. Genes Immun 7:522-531, 2006.
58. van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van de Voort E, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 3:e1927, 2008.
59. Vartanian TK, Zamvil SS, Fox E, Sorensen PS. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 63:S42-S49, 2004.
60. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199:971-979, 2004.
61. Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BMJ, Crusius JBA, van der Pouw Kraan TC, Comabella, M , Montalban X, Hafler DA, De Jager PL, Killestein J, Polman CH, Verweij CL. Interferon Response Factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in Multiple Sclerosis. Genes Immun 12:466-472, 2011.
62. Wandinger KP, Sturzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, McFarland HF, Martin R. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 50:349-357, 2001.
63. Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, Hall D, Baier M, Feichter J, Ramanathan M. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 171:2694-2702, 2003.
64. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2:777-780, 2001.
65. Williams GJ, Witt PL. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J Interferon Cytokine Res 18:967-975, 1998.
66. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695-705, 1995.
67. Yen JH, Kong W, Ganea D. IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9. J Immunol 184:3478-3486, 2010.